Lexaria Bioscience Corp.
LEXXW
NASDAQ Capital Market0.00
USD
+0.00
- -
Lexaria Bioscience Corp.
LEXXW
(NASDAQ Capital Market)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) develops DehydraTECH, a proprietary drug delivery platform technology that enhances the oral bioavailability of active pharmaceutical ingredients and bioactive compounds by combining them with long-chain fatty acid-rich carriers to improve absorption, onset speed, blood-brain barrier penetration and tolerability; the technology applies to small and large molecules including GLP-1/GIP drugs such as semaglutide, tirzepatide and liraglutide, CBD, nicotine and analogs, antivirals, vitamins, hormones, NSAIDs and cannabinoids across formats like tablets, capsules, oral suspensions, pouches, foods and beverages for pharmaceuticals, nutraceuticals and consumer products. Founded in 2004 and headquartered in Kelowna, British Columbia, Canada, with U.S. operations in Phoenix, Arizona, the company operates through subsidiaries including Lexaria Pharmaceutical Corp. for hypertension, antivirals and epilepsy applications; Lexaria Nicotine LLC for non-combusted oral nicotine products; Lexaria Hemp Corp. for hemp-derived ingredients; Lexaria Canpharm ULC, a Health Canada-licensed lab for cannabinoid formulations; and Lexaria Nutraceutical Corp. for consumer goods, while sub-licensing DehydraTECH globally and holding 56 granted patents with more pending in key markets. It targets therapeutic areas such as diabetes, obesity, hypertension, heart disease, epilepsy and weight management, serving pharmaceutical, nutraceutical and consumer sectors primarily in North America and internationally. Recent developments include closing a $4.0 million registered direct offering in September 2025 to fund 2026 R&D and business development; extending a material transfer agreement with an unnamed pharmaceutical company through April 2026 for DehydraTECH evaluation following preclinical pharmacokinetics and review of GLP-1-H24-4 human study data; completing multiple GLP-1/GIP studies in fiscal 2025 such as WEIGHT-A24-1 showing superior weight loss and blood sugar control versus Rybelsus in obese diabetic rats, GLP-1-H24-3 and GLP-1-H25-5 demonstrating reduced adverse events and comparable efficacy to injectables like Zepbound and Saxenda in humans, and GLP-1-H24-4 reaching last patient last visit with interim 8-week data indicating 43.5-56.5% fewer gastrointestinal events; advancing a FDA-cleared IND for Phase 1b hypertension trial with DehydraTECH-CBD under 505(b)(2) pathway; and granting new patents in fiscal 2025 for epilepsy, diabetes, nicotine and food applications.